CPTx appoints Edward Rebar as Chief Scientific OfficerRebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector platform
CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual MeetingOral presentation includes early readouts from preclinical testing of CAR-encoding episomal DNA delivered by targeted lipid nanoparticles
